Aethlon Medical has entered into an agreement with NAMSA, a MedTech Contract Research Organization offering global end-to-end development services to oversee the company’s clinical trials investigating the Hemopurifier, Aethlon’s immunotherapeutic device , for oncology indications. Pursuant to the agreement, NAMSA will manage Aethlon’s study of the Hemopurifier for patients in the U.S. and Australia with various types of cancer tumors. It is anticipated the initial clinical trials will begin in Australia.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AEMD:
